0000000000709224

AUTHOR

K. Huber

showing 2 related works from this author

Progression From Paroxysmal to Persistent Atrial Fibrillation. Clinical Correlates and Prognosis

2010

Objectives: We investigated clinical correlates of atrial fibrillation (AF) progression and evaluated the prognosis of patients demonstrating AF progression in a large population. Background: Progression of paroxysmal AF to more sustained forms is frequently seen. However, not all patients will progress to persistent AF. Methods: We included 1,219 patients with paroxysmal AF who participated in the Euro Heart Survey on AF and had a known rhythm status at follow-up. Patients who experienced AF progression after 1 year of follow-up were identified. Results: Progression of AF occurred in 178 (15%) patients. Multivariate analysis showed that heart failure, age, previous transient ischemic attac…

MaleTime FactorPrognosiRisk FactorpredictionMiddle AgedRisk AssessmentSeverity of Illness IndexAtrial FibrillationDisease ProgressionepidemiologyFemaleatrial fibrillation; epidemiology; prediction; prognosis; progression; Aged; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Prognosis; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Disease ProgressionprogressionAgedHuman
researchProduct

Open-label ODYSSEY APPRISE study: Interim data from the first 843 participants

2018

Background PCSK9 inhibitors (PCSK9i) have been recommended by the ESC/EAS Task Force in very high risk subjects with ASCVD and those with heterozygous familial hypercholesterolemia (HeFH) with persistent high LDL-C levels despite maximally tolerated LLT. Purpose ODYSSEY APPRISE (NCT02476006) is the first study to assess efficacy and safety at Week (W) 12 of the PCSK9i alirocumab (ALI) in a real-life setting prior to commercial availability. Methods APPRISE was an open-label, single-arm study, conducted in 16 European countries and Canada. Subjects with inadequately controlled lipid levels despite maximally tolerated LLT were included. Based on physician's judgment, participants received eit…

myalgiamedicine.medical_specialtyErythemabusiness.industryFamilial hypercholesterolemia030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineTolerabilityInternal medicineClinical endpointmedicineBack painmedicine.symptomCardiology and Cardiovascular MedicineAdverse effectbusiness030217 neurology & neurosurgeryAlirocumabArchives of Cardiovascular Diseases Supplements
researchProduct